Abstract
Combating the evolving health threat posed by carbapenem-resistant Acinetobacter baumannii (CRAb) requires knowing how this non-commensal organism establishes regional pools and propagates among at-risk hosts. We report a 2017-2019 surge of CRAb among patients receiving care in a USA multicenter system. This surge occurred during a period of sustained reduction in hospital-acquired CRAb infections and coincided with marked reduction of CRAb cases associated with distinctly more resistant antibiotypes. Isolate whole genome sequencing revealed surge isolates belonged to an emergent Pasteur scheme sequence type 499 (ST499Pas). Detailed query of health records guided by isolate genome comparative analyses revealed multiple clonal clusters linked to various outpatient healthcare settings (i.e., long term healthcare facilities, surgical and wound clinics, and other unidentified factors) but no evidence of a shared intrahospital source. We show that emergent CRAb lineages can rapidly establish a regional presence even without gains in breadth of antibiotic resistance and negligible contribution from sustained intrahospital transmission. The emergence of ST499Pas despite regional eradication of other CRAb lineages shows how control efforts could be sidestepped via outpatient epidemiological niches. We also establish an approach to investigate the propagation of CRAb lineages that can inform subsequent local surveillance efforts outside of hospital settings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by awards to G.D. through the National Institute of Allergy and Infectious Diseases and the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health (NIH) under award numbers U01 AI123394 and R01 HD092414, and awards to J.J.C by the NIH under award number K08 AI148582. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board of Washington University in St. Louis (IRB# 201707046 and 201707049). A waiver of informed consent was granted as all specimens and clinical records were obtained during routine clinical care and many patients were already deceased or would otherwise have been unable to be contacted.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are present in the manuscript, available online or upon reasonable request to the authors. Sequence read files and constructed genomes for sequenced isolates are available on NCBI under BioProject PRJNA739144, and BioSample accession numbers SAMN19774044-4250. The datasets used and analyzed during the current study are available from JJC on reasonable request. Access to retrospective clinical case datasets including patient demographics and specific dates is restricted due to patient privacy protections.
